CEO to Present at Major Industry Summit as Company Gains Momentum in Personalized Cancer Treatment
BOSTON – July 23, 2025 – Andarix Pharmaceuticals, a clinical-stage biotechnology company pioneering targeted peptide therapies for rare cancers, today announced that CEO Chris Adams will present at the 3rd Targeted Radiopharmaceuticals Supply Chain & Manufacturing Summit in Boston on July 23-24, 2025. The invitation underscores growing industry recognition of Andarix’s innovative approach to personalized cancer treatment.
Addressing Critical Unmet Need in Rare Cancers
Andarix is developing a proprietary platform that combines diagnostic imaging agents with targeted therapies to identify and treat patients with rare cancers. The company’s technology leverages somatostatin peptide conjugates, which target receptors that are highly up-regulated on several solid tumors, including lung, pancreatic, and neuroendocrine cancers.
“Our dual approach—first identifying appropriate patients through imaging, then delivering targeted therapy—represents a significant advance in personalized oncology,” said Chris Adams, CEO of Andarix Pharmaceuticals. “We’re developing solutions for patient populations that have historically been underserved due to the challenges of rare disease clinical development.”
Clinical Progress and Market Opportunity
The company’s lead products have successfully progressed through early clinical development, demonstrating the potential of the Andarix platform. The technology addresses cancers with significant unmet medical need:
- Neuroendocrine tumors: A rare but growing cancer diagnosis
- Pancreatic cancer: One of the deadliest forms of cancer with limited treatment options
- Lung cancer: The leading cause of cancer death worldwide, with certain subtypes amenable to targeted therapy
Strategic Focus on Clinical Excellence
Adams’ presentation at the TRP Summit will focus on best practices for clinical trial execution in rare diseases, including early regulatory engagement, patient advocacy collaboration, and novel approaches to patient recruitment and retention—all critical factors for successful rare disease drug development.
The summit brings together industry leaders, clinical operations professionals, and patient advocacy groups to address the unique challenges of developing therapies for rare and complex diseases.
Investment Highlights
- Differentiated Technology Platform: Proprietary somatostatin peptide conjugates with broad applicability across multiple cancer types
- De-risked Clinical Development: Lead products have advanced through early clinical trials
- Personalized Medicine Approach: Companion diagnostic strategy enables precision patient selection
- Large Addressable Market: Targeting multiple cancer indications with significant unmet need
- Experienced Leadership: Management team with proven track record in oncology drug development
About Andarix Pharmaceuticals
Andarix Pharmaceuticals is at the forefront of personalized cancer therapy, developing both imaging agents for patient identification and targeted treatments for rare cancers. The company’s proprietary platform is based on somatostatin peptide conjugates applicable to lung, pancreatic, neuroendocrine, and other cancers. Extensive research has validated that somatostatin receptors are highly up-regulated on several solid tumors, providing a therapeutic target for the company’s innovative approach. For more information, visit www.andarix.com.
Investor Contact
Andarix Pharmaceuticals
617-957-9858
info@andarix.com